Alaunos Therapeutics
TCRTAlaunos Therapeutics is pursuing a dual-track strategy targeting two major therapeutic areas: metabolic health and oncology. Its metabolic program focuses on an oral, non-hormonal small molecule for obesity, with promising preclinical proof-of-concept data showing weight loss and improved body composition in animal models. In parallel, its proprietary hunTR® platform enables rapid discovery and validation of novel TCRs for next-generation TCR-T cell therapies, aiming to create a pipeline of wholly owned oncology candidates.
TCRT · Stock Price
Historical price data
AI Company Overview
Alaunos Therapeutics is pursuing a dual-track strategy targeting two major therapeutic areas: metabolic health and oncology. Its metabolic program focuses on an oral, non-hormonal small molecule for obesity, with promising preclinical proof-of-concept data showing weight loss and improved body composition in animal models. In parallel, its proprietary hunTR® platform enables rapid discovery and validation of novel TCRs for next-generation TCR-T cell therapies, aiming to create a pipeline of wholly owned oncology candidates.
Technology Platform
Two core platforms: 1) A discovery platform for oral, non-incretin small molecules targeting obesity. 2) The hunTR® platform, a high-throughput TCR discovery and validation engine for developing novel TCR-T cell therapies for cancer.
Pipeline
39| Drug | Indication | Stage | Watch |
|---|---|---|---|
| doxorubicin in combination with palifosfamide-tris + doxorub... | Soft Tissue Sarcoma | Phase 3 | |
| Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin | Extensive-Stage Small Cell Lung Cancer | Phase 3 | |
| Palifosfamide Tris and Doxorubicin + Doxorubicin | Soft Tissue Sarcoma | Phase 2 | |
| Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc | Glioblastoma | Phase 2 | |
| palifosfamide | Adult Central Nervous System Germ Cell Tumor | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
In obesity, Alaunos competes directly with Novo Nordisk and Eli Lilly's dominant incretin therapies and a crowded pipeline of oral successors. Its differentiation is a non-hormonal mechanism aiming for better tolerability. In TCR-T cell therapy, it competes with Adaptimmune, Immunocore, and others, differentiating through its proprietary hunTR® high-throughput discovery platform.